Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agile nudge implementation to improve minority recruitment in community-based research.

Frontiers in health services·2026
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Early prediction of postoperative delirium in major surgery patients using multimodal preoperative EHR and medical notes: a retrospective cohort study in the Indiana network for patient care.

BMJ public health·2026
Same author

Corrigendum to 'Association Between State Essential Caregiver Programs and Antipsychotic Medication Use Rate in Nursing Homes During the COVID-19 Pandemic' The American Journal of Geriatric Psychiatry Volume 34, Issue 5, May 2026, Pages 747-758.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Atomistic Origin of RTN-like Centers Created and Annihilated by RRAM Write Processes.

Nano letters·2026
Same author

Payer mix shifts and profitability at critical access hospitals, 2011 to 2023.

Health affairs scholar·2026

Related Experiment Video

Updated: May 16, 2026

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Long-term anticholinergic use and the aging brain.

Xueya Cai1, Noll Campbell, Babar Khan

  • 1Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|November 28, 2012
PubMed
Summary

Anticholinergic (AC) medication exposure in older adults is linked to a higher risk of mild cognitive impairment (MCI). This study found that exposure to multiple ACs for 90 days increased MCI odds, highlighting potential risks of these drugs.

More Related Videos

Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain
09:15

Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain

Published on: February 5, 2020

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
14:57

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

Related Experiment Videos

Last Updated: May 16, 2026

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain
09:15

Stereological Estimation of Cholinergic Fiber Length in the Nucleus Basalis of Meynert of the Mouse Brain

Published on: February 5, 2020

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
14:57

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

Area of Science:

  • Gerontology
  • Pharmacology
  • Neuroscience

Background:

  • Older adults face a chronic disease epidemic, increasing exposure to anticholinergic (AC) medications.
  • ACs may negatively impact cognitive function, potentially increasing the risk of mild cognitive impairment (MCI) and dementia.

Purpose of the Study:

  • To investigate the association between previous anticholinergic (AC) exposure and cognitive function impairment in older adults.
  • To determine if AC exposure is a risk factor for developing MCI or dementia.

Main Methods:

  • Retrospective cohort study involving 3690 older adults from primary care clinics.
  • Cognitive function assessed via a two-step screening and diagnostic process.
  • Anticholinergic exposure categorized by duration, number of medications, and severity using the Anticholinergic Cognitive Burden list.

Main Results:

  • Older adults exposed to at least three ACs for 90 days had an odds ratio of 2.73 for MCI.
  • No significant association was found between AC exposure and dementia (odds ratio 0.43).
  • Adjustments were made for age, race, gender, and comorbidity.

Conclusions:

  • Exposure to medications with a high anticholinergic cognitive burden may be a significant risk factor for developing mild cognitive impairment (MCI).
  • Further research is warranted to explore the long-term effects of ACs on cognitive health in the elderly.